Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

2 Pages (Click to Jump) V   1 2 >   
 
  
Reply to this topic

PAL, PALLA PHARMA LIMITED
nipper
post Posted: Nov 3 2019, 11:46 AM
  Quote Post


Posts: 6,312
Thanks: 2225


QUOTE
Palla Pharma (formerly TPI Enterprises)

Palla is an internationally licenced narcotic producer supplying pain relief products. It has fully integrated operations taking product from the farm gate to tablet production and has operations in Victoria and Norway.

Palla has developed an innovative, efficient and environmentally sustainable water-based method for extracting narcotic raw material from opium poppies. Its manufacturing cost advantage is central to its strategy to achieve significant market share growth.

For the six months ended 30 Jun 2019, Palla reported the following results which are compared to those of the first half last year:
- Record revenue of $27.3 million, up 20.3%.
- Gross profit margin of 34.6%, up 126 bps.
- Operating earnings before interest and tax up $2.1 million, to $0.3 million.
- Underlying net loss of $2.3 million (2018 $3.9 million loss).

Increases in Narcotic Raw Material extraction rates and Active Pharmaceutical Ingredient production led to a substantial improvement in operational efficiencies and an enhanced gross profit margin. Palla plans to increase its Active Pharmaceutical Ingredient production by a further 50% by the end of its 2019 financial year.

too bad about the opioid Crisis



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Aug 31 2019, 03:42 PM
  Quote Post


Posts: 6,312
Thanks: 2225


Tasmanian farmers ride out the US opioid crisis

QUOTE
Selling pain relief drugs just got a whole lot more complicated.

Earlier this week, an Oklahoma court fined Johnson & Johnson $US572 million ($852 million) for contributing to (that) state's over-prescription crisis; a judgement that is expected to trigger many more.

It's also been revealed that Purdue Pharma, the maker of "hill billy heroin" OxyContin, is negotiating a $US10 billion to $US12 billion deal to settle and prevent further lawsuits. This could see the billionaire Sackler family give up ownership of the company.

Australia might seem a long way from the US opioid crisis. But in fact, thanks largely to Tasmania, we supply more than half the of world's raw materials for pain-relief drugs.

Fields of pale pink opium poppies are typically harvested in late January and February and then delivered in closely counted sealed containers to the three opium processors.

While the legal fallout from the opioid crisis probably still has years to run, the market has largely adjusted to weaker US demand, says Jarrod Ritchie, a former chemist who now runs the country's third-largest poppy processor.

"I don't believe there will be any impact [from the Oklahoma judgment, which J&J is appealing] to the Australian poppy industry," Ritchie says.

Ritchie has worked in the sector "since he had hair", he says, founding TPI Industries, a challenger to the country's two other opium buyers and processors in 2004 after leaving GlaxoSmithKline.

TPI - now the $94 million sharemarket-listed Palla Pharma - is backed by some of the country's most successful investors, including Thorney Investments' Alex Waislitz, Washington H Pattinson's Robert Millner and Simon Moore, the former country head of private equity giant Carlyle Investments.

It's one of just three growers and processors in the country and the only one that operates outside of Tasmania. The other two are SunPharma, originally GlaxoSmithKline then bought by the Indian pharmaceutical company, and Tasmanian Alkaloids, which was bought from Johnson & Johnson by New York private equity firm SK Capital in 2016.

It was Tasmanian Alkaloids, then owned by Johnson & Johnson, that was named in the Oklahoma trial for developing the high thebaine "Norman poppy" in anticipation of more OxyContin demand.

Oklahoma's Attorney-General Mike Hunter said between 2015 and 2018, 18 million opioid prescriptions were written in a state with a population of 3.9 million. Since 2000, his office said, about 6000 Oklahomans have died from opioid overdoses, and thousands more are struggling with addiction.

Tasmanian Alkaloids' chief executive Ross Murdoch says it's hard to predict where the local industry will go. "Certainly in the US, people believe the decrease in demand has stabilised. What that means for the Australian supply is difficult to predict, companies don't only draw supply from Australia," he says,

In Tasmania and other parts of Australia, farmers have begun sowing next year's poppy crop.

Ritchie might be upbeat about the industry's prospects and the need for its products - he points out that 75 per cent of the world's population doesn't have access to essential medicine - but the boom times for poppy farmers are definitely over.

Narcotic raw material pricing - known as NRM - has fallen to the lowest point in about 10 years, partly driven lower by less demand from the US. NRM sales pricing is now between $US350 and $US280 compared to historical levels of between $US450 and $US500...

Many farmers are choosing to sow other crops over poppies. In 2018, just 11,949 hectares were harvested in Tasmania, compared to 21,428 hectares in 2013.

Ritchie says there's far more to this than lower - hopefully bottoming - demand from US, noting Palla mainly sells morphine and codeine into Europe. In particular, Australia's investment in research and processing techniques have changed industry dynamics.

Take productivity. About 15 years ago, the poppy industry was delivering an average of 8 kg a hectare. Now it's closer 30kg a hectare.

Poppies are not an easy crop. Tight regulations control the process, including regular crop inspections, required visitor sign-ins and reporting of any theft.

Poppies can also require a lot of expensive and time-consuming spraying, and the plants can't have "wet feet" for more than eight hours. (There's another challenge in India, where parrots, often seen crashing into tree branches and lying in a daze, were reportedly ravaging crops after becoming addicted to opium.)

Farmers typically begin sowing in late May and finish no later than mid-October. Harvest can begin as early as late December.

"So far this year is looking OK," says Ritchie. "Last year was a bumper year, the biggest ever at the lowest price."

Processing techniques have also improved. In fact, Ritchie says Palla's own cheaper processing - which uses a secret, non-patented water-based method to extract the opium from the poppy capsule - is a key ingredient in keeping NRM prices down. Poppy processors also extract seeds, which are then sold to bakeries and other food manufacturers.

"We're happy to compete on price," he says, noting Palla has brought more capacity into the market as well.

As Palla Pharma ramps up, Tasmanian Alkaloids is diversifying away from poppies and into other crops, including cannabis.

"We're looking at options to grow beyond poppy plants - it's our future, poppies are part of that, but we're a broader business now," Murdoch said. "Our role is to improve plants that can be used for extracts. Poppies are just one of them."

https://www.afr.com/companies/healthcare-an...20190828-p52lhu



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Sep 29 2017, 12:53 PM
  Quote Post


Posts: 6,312
Thanks: 2225


Received medical cannabis licenses - to add to the suite of controlled drugs



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jul 12 2017, 06:04 PM
  Quote Post


Posts: 6,312
Thanks: 2225


after being on the nose for a while, and going sub $2, TPE has had 2 recent actions (and closed above $2.50 today)

- second UK supply agreement signed ... now supplying close to 20% of UK Codeine Phosphate

- European acquisition - Vision Opiates -> giving integrated production, manufacturing and marketing






--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jun 23 2017, 08:58 AM
  Quote Post


Posts: 6,312
Thanks: 2225


opioid induced hyperalgesia

The opioid curse: Lives lost as patients addicted to painkillers prescribed dozens of drugs ... Dr Simon Holliday, an addiction specialist, said it becomes more common the longer a patient is on opioids. "With opioids it turns up the amplification of sensation and pain so that what could be a tolerable pain becomes absolutely unbearably distressing,"

http://www.abc.net.au/news/2017-06-23/opio...stralia/8638980



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: May 17 2017, 05:05 PM
  Quote Post


Posts: 6,312
Thanks: 2225


with Painkillers containing codeine not available over the counter from 2018 in this country,
http://www.abc.net.au/news/2016-12-20/code...er-2018/8133996

and from the experience in other jurisdictions, is likely that this country is in for 'substitution' and the illegality that implies.
http://www.webmd.com/mental-health/addicti...ip-on-america#1

Particularly scary is the transition to heroin-fentanyl , a powerful synthetic opioid.
QUOTE
Millions of Americans got hooked on pain pills during a prescription binge that started in the 1990s and peaked around 2011. As states have tightened monitoring and doctors have reduced dosages, it's become harder for addicts to get prescription painkillers, driving many to get their fix off street drugs.
https://www.bloomberg.com/news/features/201...ming-in-america





--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 

sentifi.com

Share Cafe Sentifi Top themes and market attention on:


nipper
post Posted: Aug 30 2016, 02:10 PM
  Quote Post


Posts: 6,312
Thanks: 2225


In Reply To: nipper's post @ Jun 4 2016, 08:44 AM

all going ticketty-boo, apart from:
Earlier this year EDQM adopted a different view on quality requirements for the supply of Morphine NRM for the manufacture of Codeine Phosphate API and now considers NRM to be classed as an intermediate, requiring manufacture under GMP conditions. This change delayed the placement of orders by customers.

hard to get that cash spend under control, when there are delays to any moolah coming in.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jun 4 2016, 08:44 AM
  Quote Post


Posts: 6,312
Thanks: 2225


In Reply To: nipper's post @ Jun 1 2016, 08:48 AM

I wonder if this is an "inconvenient truth", though the impact may not be too great (what are the alternatives?)

Morphine prolongs and worsens pain, Australian-US study finds

QUOTE
Australian and US researchers have found that morphine can dramatically prolong pain and make it more severe. The report, published .. in the journal PNAS, emerges amid concern over the long-term effects of morphine and other opioid drugs. Soaring prescription rates and a mounting overdose death toll have sparked calls for more study into morphine's long-term consequences. The new study suggests that as well as addictive properties and risk of fatal accidents, the drug extends the original trauma.

"Our results add weight to the growing body of science suggesting that opioids may in fact be a contributor to people's chronic pain," said lead author Peter Grace, a pharmacologist who shares his time between the University of Adelaide and the University of Colorado Boulder.

He said it had long been known that certain injuries provoked an immune response from "glial" cells in the spinal cord. "More recently we've learnt that opioids activate the same immune cells. We wanted to test (whether) both of those challenges — a nerve injury as well as opioids — (produce) an exaggerated inflammatory response."

The researchers simulated nerve injuries in rats by tying ligatures around their sciatic nerves, and gave some of them morphine for five days. They took 10-11 weeks to recover, compared with about five weeks for animals that had not received morphine.

Co-author Linda Watkins said the "one-two hit" of injury and opioids pushed the immune response into overdrive. "The glial cells explode into action, making pain neurons go wild."

Dr Grace said the findings related to nerve pain such as sciatica and shingles. More research was needed to determine whether opioid treatment of conditions such as lower back pain and fibromyalgia triggered a similar cascading immune response.

He said while it would be inadvisable to stop using opioids altogether, non-opioid alternatives such as pregabalin and amitripline should be considered first. "(Morphine) works really well to begin with, (but) we're just now starting to understand some of these negative consequences. "

The team found a drug related to a heroin overdose medication could stop the immune over-­reaction, suggesting it could be taken with morphine to prevent the runaway inflammation.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jun 1 2016, 08:48 AM
  Quote Post


Posts: 6,312
Thanks: 2225


In Reply To: nipper's post @ May 23 2016, 01:33 PM

delete



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: May 23 2016, 01:33 PM
  Quote Post


Posts: 6,312
Thanks: 2225


keeping the market informed - up 7%

TPE is pleased to provide the following update which outlines a number of significant milestones that have been achieved during the first 4 months of this year.

1. European Directorate for the Quality of Medicines (EDQM) qualification granted
TPE's new Victorian site has now been qualified in accordance with ICH Q7 "Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients", making TPE an approved supplier of Narcotic Raw Material (NRM) under the EDQM requirements.

2. Customer audits 100% successful
Several recent customer audits of TPE´s Victorian site have now been completed with positive outcomes in all cases. The level of demand is such that TPE remains confident that it will deliver on its target of supplying 100 tonnes of NRM by 2019.

3. Importation approvals on track
On October 30 2015 TPE applied for the ability to import poppy straw from European countries, specifically; Portugal, Turkey and Hungary. Approval will enable TPE to commercially benefit from northern hemisphere growing seasons and import material from the above stated countries...

4. Portugal validation plant approvals granted
The full site change licence is expected by November 2016 and will allow TPE to operate as an API manufacturer at the Mems Martins site from 2018 once the full scale equipment has been installed, qualified and audited.

5. Industrial Hemp licence granted
TPE has received a licence to grow and extract Industrial Hemp for experimental purposes. While this is not a licence for medicinal cannabis, it enables TPE to more fully investigate and understand the agronomic and extraction requirements to produce cannabis based products under GMP conditions should the Federal and State government elect to engage with commercial entities.

6. More mainland states expected to approve poppy growing
In November 2015 the South Australian government passed legislation to allow the growing of poppies. It is expected that the regulations will be in place before the end of Q3 2016 which will allow for growing in 2017. TPE has already invested in a field officer in South Australia to take advantage of the significant area under irrigation around the Mt Gambier /Naracoorte area. TPE is in discussion with the New South Wales government and expects that legislation/regulations will be in place before the end of Q4 2016. As a result of this TPE expects to be growing in Victoria, Tasmania, New South Wales, South Australia and the Northern Territory in 2017 which will dramatically increase the opportunities for, and security of supply of, raw material across different climatic regions and different timelines.

7. Increased Tasmanian growing quota approved
TPE has seen a significant increase in demand for contracts to grow in Tasmania and has now sought permission to grow nearly double the quantity of poppies than originally anticipated. This request for additional area has been approved by the Poppy Advisory Control Board which regulates Tasmanian poppy growing. The increased demand for contracts from TPE comes after the significant cutbacks in growing area made by TPE´s Australian competitors. As has been reported publically TPE´s Tasmanian competitors have accumulated significant stockpiles of poppy straw and have been reducing the area grown in Tasmania from a peak of approximately 27,000 Ha in 2014 to less than 7000 Ha expected this year. By contrast TPE is growing market share and expects to grow its biggest crop ever in the 2016/17 growing season.

8. Agricultural yields improving
In the 2015/16 growing season TPE crops improved 30% in terms of yield/Ha compared to the previous year. TPE expects this level of improvement to continue with the 2016/17 growing season off to a good start after well timed rain in Victoria and Tasmania. TPE is currently sowing the largest ever paddock of poppies in Australia with a total paddock size of 400 Ha situated in the north of Victoria. At this stage TPE is on track to contract sufficient area to supply its expected needs for the 2017 production season.

9. New process to increase manufacturing yield
TPE has recently developed a novel column extraction process for the recovery of previously unrecovered trace quantities of NRM in waste streams at its new Victorian processing facility



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
 


2 Pages (Click to Jump) V   1 2 >

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING